Bupropion: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antidepressant *Dosage Forms: *Routes of Administration: oral *Common Trade Names: Wellbutrin, Zyban, Forfivo ==Adult Dosing== *Immediate release: 1...") |
(edited dosage forms, strengths, routes of administration, trade names) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antidepressant | *Type: Antidepressant | ||
*Dosage Forms: | *Dosage Forms: tablet, sustained-release tablet, extended-release tablet | ||
*Routes of Administration: | *Dosage Strengths: tablet: 75, 100mg; sustained-release tablet (Wellbutrin SR): 100, 150, 200mg; extended-release tablet (Wellbutrin XL): 150, 300mg; extended-release tablet (Aplenzin): 174, 348, 522mg; extended-release tablet (Forfivo XL): 450mg; extended-release tablet (Zyban): 150mg | ||
*Common Trade Names: Wellbutrin, Zyban, Forfivo | *Routes of Administration: PO | ||
*Common Trade Names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Forfivo XL, Budeprion SR, Aplenzin, Buproban | |||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 23:31, 11 October 2017
Administration
- Type: Antidepressant
- Dosage Forms: tablet, sustained-release tablet, extended-release tablet
- Dosage Strengths: tablet: 75, 100mg; sustained-release tablet (Wellbutrin SR): 100, 150, 200mg; extended-release tablet (Wellbutrin XL): 150, 300mg; extended-release tablet (Aplenzin): 174, 348, 522mg; extended-release tablet (Forfivo XL): 450mg; extended-release tablet (Zyban): 150mg
- Routes of Administration: PO
- Common Trade Names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Forfivo XL, Budeprion SR, Aplenzin, Buproban
Adult Dosing
- Immediate release: 100-150mg PO 2-4 times daily
- Sustained release: 150mg PO 1-2 times daily
Pediatric Dosing
Safety/efficacy not established]]
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk cannot be ruled out
- Renal dosing: dose reduction or avoidance recommended
- Hepatic dosing: dose reduction or avoidance recommended
Contraindications
- Allergy to class/drug
- Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks
- Seizure disorder
- Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement)
Adverse Reactions
Serious
- Seizure
- Cardiac dysrhythmia
- Angle-closure glaucoma
- Suicidal ideation, worsening depression, mania, psychosis
Common
- Insomnia
- Dizziness, tremor
- Headache
- Nausea, constipation
- Tachyarrhythmia (10.8% )
- Pruritus, rash, urticaria
- Arthralgia, myalgia
- Tinnitus
- Xerostomia, pharyngitis
Pharmacology
- Half-life: 14-33h
- Metabolism: Hepatic, CYP2B6
- Excretion: Mostly renal
Mechanism of Action
- Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine